SG11202110469PA - Ghrh or analogues thereof for use in treatment of hepatic disease - Google Patents
Ghrh or analogues thereof for use in treatment of hepatic diseaseInfo
- Publication number
- SG11202110469PA SG11202110469PA SG11202110469PA SG11202110469PA SG11202110469PA SG 11202110469P A SG11202110469P A SG 11202110469PA SG 11202110469P A SG11202110469P A SG 11202110469PA SG 11202110469P A SG11202110469P A SG 11202110469PA SG 11202110469P A SG11202110469P A SG 11202110469PA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutically acceptable
- hexenoyl
- acceptable salt
- subject
- trans
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826284P | 2019-03-29 | 2019-03-29 | |
| US201962861187P | 2019-06-13 | 2019-06-13 | |
| PCT/US2020/025180 WO2020205498A1 (en) | 2019-03-29 | 2020-03-27 | Ghrh or analogues thereof for use in treatment of hepatic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110469PA true SG11202110469PA (en) | 2021-10-28 |
Family
ID=72607731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110469PA SG11202110469PA (en) | 2019-03-29 | 2020-03-27 | Ghrh or analogues thereof for use in treatment of hepatic disease |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10799562B1 (https=) |
| EP (1) | EP3947426A4 (https=) |
| JP (1) | JP2022527190A (https=) |
| KR (1) | KR20210145226A (https=) |
| CN (1) | CN113646327A (https=) |
| AU (1) | AU2020253828A1 (https=) |
| CA (1) | CA3133319A1 (https=) |
| IL (1) | IL286703A (https=) |
| SG (1) | SG11202110469PA (https=) |
| WO (1) | WO2020205498A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202110469PA (en) | 2019-03-29 | 2021-10-28 | Massachusetts Gen Hospital | Ghrh or analogues thereof for use in treatment of hepatic disease |
| CN115884783A (zh) * | 2020-07-05 | 2023-03-31 | 瑟瑞技术公司 | Ghrh类似物的低剂量药物组合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101678083A (zh) * | 2007-04-04 | 2010-03-24 | 瑟瑞技术公司 | Ghrh分子的药物制剂 |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US20150174207A1 (en) * | 2013-12-24 | 2015-06-25 | University Of Miami | Methods for treating cancer with ghrh agonists |
| US20170105996A1 (en) * | 2015-10-16 | 2017-04-20 | Teva Pharmaceutical Industries, Ltd. | Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine |
| WO2017181277A1 (en) * | 2016-04-19 | 2017-10-26 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
| KR20200121308A (ko) * | 2018-02-14 | 2020-10-23 | 루모스 파마, 인크. | 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물 |
| SG11202110469PA (en) * | 2019-03-29 | 2021-10-28 | Massachusetts Gen Hospital | Ghrh or analogues thereof for use in treatment of hepatic disease |
| WO2022093757A1 (en) * | 2020-10-30 | 2022-05-05 | The General Hospital Corporation | Kits, reagents and methods for the assessment of liver diseases |
| US20220152012A1 (en) * | 2020-11-16 | 2022-05-19 | The Regents Of The University Of California | Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof |
-
2020
- 2020-03-27 SG SG11202110469PA patent/SG11202110469PA/en unknown
- 2020-03-27 CN CN202080025127.2A patent/CN113646327A/zh active Pending
- 2020-03-27 CA CA3133319A patent/CA3133319A1/en active Pending
- 2020-03-27 KR KR1020217034940A patent/KR20210145226A/ko not_active Ceased
- 2020-03-27 EP EP20784029.9A patent/EP3947426A4/en not_active Withdrawn
- 2020-03-27 JP JP2021557925A patent/JP2022527190A/ja active Pending
- 2020-03-27 AU AU2020253828A patent/AU2020253828A1/en not_active Abandoned
- 2020-03-27 WO PCT/US2020/025180 patent/WO2020205498A1/en not_active Ceased
- 2020-03-27 US US16/832,128 patent/US10799562B1/en active Active
- 2020-09-11 US US17/018,878 patent/US10946073B2/en active Active
-
2021
- 2021-02-08 US US17/170,579 patent/US11738066B2/en active Active
- 2021-09-26 IL IL286703A patent/IL286703A/en unknown
-
2023
- 2023-07-12 US US18/351,169 patent/US12233107B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10946073B2 (en) | 2021-03-16 |
| US11738066B2 (en) | 2023-08-29 |
| US10799562B1 (en) | 2020-10-13 |
| EP3947426A4 (en) | 2023-01-04 |
| WO2020205498A1 (en) | 2020-10-08 |
| EP3947426A1 (en) | 2022-02-09 |
| JP2022527190A (ja) | 2022-05-31 |
| US20240091316A1 (en) | 2024-03-21 |
| KR20210145226A (ko) | 2021-12-01 |
| US20200405816A1 (en) | 2020-12-31 |
| CN113646327A (zh) | 2021-11-12 |
| AU2020253828A1 (en) | 2021-10-28 |
| US12233107B2 (en) | 2025-02-25 |
| IL286703A (en) | 2021-10-31 |
| US20210177943A1 (en) | 2021-06-17 |
| US20200306345A1 (en) | 2020-10-01 |
| CA3133319A1 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3412310B1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| CN102389413B (zh) | 用于治疗糖尿病的组合物及其应用 | |
| US12233107B2 (en) | GHRH or analogues thereof for use in treatment of hepatic disease | |
| TR201906843T4 (tr) | Hızlı etkili insülin bileşimleri. | |
| EP2209528A1 (en) | Rapid acting injectable insulin compositions | |
| US20050112093A1 (en) | Combination therapy for HCV infection | |
| JP7738046B2 (ja) | 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤 | |
| WO2018171557A1 (zh) | 一种长效化突变的人源成纤维生长因子的新用途 | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| KR20240176455A (ko) | 시클로덱스트린을 포함하는 약학적 제형 | |
| US12564619B2 (en) | Stable formulations of recombinant proteins | |
| EP3856767B1 (en) | Formulations of glucagon-like-peptide-2 (glp-2) analogues | |
| US20200197494A1 (en) | Peptide compositions and methods of use | |
| EP4643862A1 (en) | Pharmaceutical composition and use thereof | |
| US20130079416A1 (en) | Homeopathic medicament comprising phenacetin for the treatment of cancer | |
| CN117018197A (zh) | 促进dock11表达的试剂作为治疗神经病理性疼痛药物的应用 | |
| CN116407614A (zh) | 一种新型三激动剂创新生物药物的稳定制剂 | |
| CN115884783A (zh) | Ghrh类似物的低剂量药物组合物及其用途 | |
| HK40050341A (en) | Formulations for improved stability of recombinant human parathyroid hormone |